I'm LongbridgeAI, I can summarize articles.BofAS raised BEONE MEDICINES'target price to HKD255.43, reiterating a Buy rating. The upgrade reflects strong 1H26 revenue growth of 32% YoY, driven by Brukinsa demand and improved gross margins. Management raised full-year 2026 revenue guidance to USD6.6-6.8 billion. Consequently, BofAS increased its revenue forecasts for 2026-2028 by 5.5%-6.9%, citing robust sales and US approval of sonrotoclax.
BofAS published a research report stating that BEONE MEDICINES (06160.HK) +4.300 (+2.155%) Short selling $144.52M; Ratio 12.134% 's total revenue for 1H26 rose 32% YoY. Among which, 2Q product revenue and total revenue increased 29% and 30% YoY to USD1.68 billion and USD1.705 billion, respectively. Revenue growth was mainly driven by continued strong global demand for Brukinsa. Gross margin in the second quarter improved by 2 ppts YoY to 90%.
The report noted that BEONE MEDICINES management further raised its full-year revenue guidance for 2026 to between USD6.6 billion and USD6.8 billion, compared with the previous guidance of between USD6.3 billion and USD6.5 billion. BofAS raised its revenue forecasts for the company for 2026-2028 by 5.5%, 6.7% and 6.9%, respectively, to reflect the company's strong sales performance in 1H26, higher guidance and the approval of sonrotoclax in the US. The broker reiterated its Buy rating and lifted the TP from HKD243.83 to HKD255.43. (sl/u)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-08-06 16:25.)